Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors
摘要:
N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (HAT), which is caused by the parasitic protozoa Trypanosoma brucei. We report the optimization of a high throughput screening hit (1) to give a lead molecule DDD85646 (63), which has potent activity against the enzyme (IC50 = 2 nM) and T. brucei (EC50 = 2 nM) in culture. The compound has good oral pharmacokinetics and cures rodent models of peripheral HAT infection. This compound provides an excellent tool for validation of T. brucei NMT as a drug target for HAT as well as a valuable lead for further optimization.
The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.
本发明涉及N-杂环磺胺化合物,特别是吡唑磺胺化合物,以及它们作为N-肉豆蔻酰转移酶抑制剂的用途。
N-MYRISTOYL TRANSFERASE INHIBITORS
申请人:Brand Stephen
公开号:US20160060224A1
公开(公告)日:2016-03-03
The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.